

SUPPLEMENTARY MATERIAL

Supplementary table S1. Clinical characteristics and SC pdC1INH dose.

							SC pdC1-INH (Berinert®) LTP						
Pt	Sex	Age ^a	Weight (Kg)	HAE-C1INH type	Previous LTP	Angioedema attacks per month, 6 months before SC pdC1-INH (Berinert®) LTP	Start date	Dose corresponding to SmPC per weight (60 IU/kg twice a week)	Dose according to GEAB protocol	Initial dose	Percent age of dosage respect SmPC	Dose at 6 months	Angioedema attacks per month, 6 months after
1	F	42	76.3	II	IV Berinert® 1,000 IU/72h	0.6/month	06/02/2018	4,578 IU twice weekly (9,156 IU/wk)	2,000 UI tpw	1,500 IU tpw (19.66 IU/kg)	32.77%	1,500 IU every 72h (24.97 IU/kg)	0.3/month
2	F	26	108.6	I	None	3.6/month	05/08/2020	6,516 IU twice weekly (13,032 IU/wk)	4,000 UI tpw	2,000 IU tpw (18.41 IU/kg)	30.69%	2,000 IU every 96h (17.25 IU/kg)	0
3	M	78	91	I	IV Cinryze® 1,000 IU/48h	1.6/month	03/09/2020	5,460 IU twice weekly (10,920 IU/wk)	2,000 UI tpw	4,000 IU tpw (43.95 IU/kg)	73.26%	4,000 IU – 2,000 IU alternating, tpw (32.96 IU/Kg)	0

4	F	42	92.6	I	IV Cinryze ® 1,000 IU/72h	2.25/month	09/09/2 020	5,556 IU twice weekly (11,112 IU/wk)	2,000 UI tpw	2,000 IU tpw (21.6 IU/kg)	36%	4,000 IU tpw (43.2 IU/kg)	0.3/mont h
5	F	44	63.4	I	None	2.75/month	23/12/2 020	3,804 IU twice weekly (7,608 IU/wk)	2,000 UI tpw	2,000 IU tpw (31.54 IU/kg)	52.58%	2,000 IU tpw (31.54 IU/kg)	0.75/mon th
6	M	54	85.3	I	Danazol 100mg/ d, 5 days per week	1.5/month	29/06/2 021	5,118 IU twice weekly (10,236 IU/wk)	2,000 UI tpw	2,000 IU tpw (23.45 IU/kg)	39.08%	4,000 IU - 2,000 IU alternating, tpw (35.16 IU/kg)	2/month
7	M	44	91.2	I	Stanazol ol 2mg/d	3/month	06/07/2 021	5,472 IU twice weekly (10,944 IU/kg)	4,000 UI tpw	2,000 IU tpw (21.93 IU/kg)	36.55%	4,000 IU - 2,000 IU alternating, tpw (32.90 IU/kg)	0
8	F	47	56.1	I	Stanazol ol 2mg/48 h	1.6/month	26/07/2 021	3,366 IU twice weekly (6732 IU/kg)	2,000 UI tpw	2,000 IU tpw (35.65 IU/kg)	59.42%	2,000 IU three times weekly (44.56 IU/kg)	2/month

Abbreviations: LTP: long-term prophylaxis, SC pdC1-INH: subcutaneous plasma-derived C1-INH, tpw: twice peer week

^aAge (years) at initiation of SC pdC1-INH

Supplementary table S2. AE-QoL (median, IQ₂₅₋₇₅).

AE-QoL	Functioning	Fatigue/Mood	Fear/Shame	Food	Total Score
Before	34.4 (1.6 –	45.0 (10-70)	54.2 (18.8 –	43.8 (0- 81.3)	44.1 (55.9%)
LTP C1- INH (SC)	67.2)		65.6)		(12.9 – 66.2)
After 6 months	6.9 (0-56.3)	47.5 (12.5 –	27.1 (7.3 –	37.5 (3.1 –	33.8 (66,2%)
LTP C1- INH (SC)		65.0)	66.7)	68.8)	(12.1 – 61.8)
p	<i>P = 0.496</i>	<i>P = 0.496</i>	<i>P = 0.149</i>	<i>P = 0.672</i>	<i>P = 0.237</i>

Abbreviations: AE-QoL: Angioedema quality of life questionnaire. LTP: long-term prophylaxis. SC pdC1-INH: subcutaneous plasma-derived C1-INH.

Supplementary table S3. HAE-QoL: (median, IQ₂₅₋₇₅).

HAE-QoL	Physical functioning and health	Disease-related stigma	Emotional role and social functioning	Concern about offspring	Perceived control over illness	Mental health	Treatment difficulties	Total score
Before LTP C1-INH (SC)	17.0 (13.8 – 19.8)	12.0 (9.3 – 13.8)	14.5 (10.5 – 18.0)	3.0 (3.0 -10.0)	14.5 (5.5 – 15.0)	16.0 (12.3 – 21.0)	19.0 (14.0 – 23.0)	98.0 (72,6%) (76.3 -112.8)
After 6 months LTP C1-INH (SC)	21.0 (16.0 - 23.0)	11.5 (9.0 - 14.8)	16.0 (11.3 - 19.8)	4.5 (2.5 - 9.3)	15.0 (11.0 - 16.0)	21.0 (17.0 -23.5)	20.0 (14.0 -23.0)	112.0 (83%) (84.8 -125.0)
p	<i>P = 0.141</i>	<i>P = 1.000</i>	<i>P = 0.732</i>	<i>P = 0.786</i>	<i>P = 0.031*</i>	<i>P = 0.020*</i>	<i>P = 0.593</i>	<i>P = 0.093</i>

Abbreviations: HAE-QoL: Specific health-related quality of life questionnaire for adult patients with hereditary angioedema due to C1 esterase inhibitor deficiency. LTP: long-term prophylaxis. SC pdC1-INH: subcutaneous plasma-derived C1-INH.

Supplementary table S4. TSQM v.1.4 measured after 6 months LTP C1-INH (SC).

Patient	Effectiveness	Side Effects	Convenience	Overall Satisfaction
1	94.4	0	100	85.8
2	83.3	0	55.5	100
3	-	-	-	-
4	72.2	0	72.2	77.7
5	50	37.5	44.4	50
6	100	0	72.2	100
7	77.7	0	66.6	94.4
8	33.3	62.5	55.5	36.1

Abbreviations: TSQM: Treatment Satisfaction and Medical Outcomes.

Supplementary table S5. Individual patient HAE activity and HRQoL

Pt	HAE activity and AE-QoL/HAE-QoL Total Score 6 months before SC pdC1INH (Berinert®) LTP			HAE activity and AE-QoL/HAE-QoL Total Score after 6 months with SC pdC1INH (Berinert®) LTP		
	Angioedema attacks per month	AE-QoL total Score (%*)	HAE-QoL total Score (%**)	Angioedema attacks per month	AE-QoL total Score (%*)	HAE-QoL total Score (%**)
1	0.6	57.4 (42.7%)	77 (57.0%)	0.3	25.0 (75.0%)	117 (86.7%)
2	3.6	8.8 (91.2%)	122 (90.4%)	0	8.8 (91.2%)	128 (94.8%)
3	1.6	2.9 (97.1%)	100 (70.1%)	0	48.5 (51.5%)	107 (79.3%)
4	2.3	55.9 (44.1%)	76 (56.3%)	0.3	42.6 (57.4%)	84 (62.2%)
5	2.8	98.5 (1.5%)	47 (34.8%)	0.8	92.6 (7.4%)	44 (32.6%)
6	1.5	32.4 (67.6%)	109 (80.7%)	2	22.1 (77.9%)	125 (92.6%)
7	3	25.0 (75.0%)	114 (84.4%)	0	1.5 (98.5%)	125 (92.6%)
8	1.6	69.1 (30.9%)	96 (71.1%)	2	66.2 (33.8%)	87 (64.4%)

Abbreviations: LTP: long-term prophylaxis, SC pdC1INH: subcutaneous plasma-derived C1-inhibitor

AE-QoL Total Score (0-100): A higher total score corresponds to a poorer quality of life. *To calculate the percentage of the total score with respect to the maximum score (0), we subtracted the total score from 100.

HAE-QoL Total Score (25-135): A higher total score corresponds to a better quality of life. **The total HAE-QoL score is also shown as a percentage of the maximum score.